Quest PharmaTech Completes the Enrollment of Patients in Phase I Clinical Study of SL017 Topical Gel for Photodynamic Therapy of Actinic Keratosis



    Trading Symbol: QPT: TSX Venture Exchange

    EDMONTON, June 13 /CNW/ - Quest PharmaTech Inc. ("Quest" or the
"Company") Quest is pleased to announce that patient enrollment has been
completed in the Phase I clinical study of SL017 Topical Gel for the
photodynamic therapy of actinic keratosis (AK), with centers in Edmonton and
Montreal.
    The clinical trial is a controlled, randomized, open label, dose
escalation study for the topical application of SL017 Topical Gel in twelve
patients with AK. The study is designed to determine the cutaneous and
systemic toxicity of topically applied SL017 with and without photoactivation,
and to evaluate clinically and pathologically the therapeutic effect of
applying photodynamic therapy (PDT) to AK. The patients will continue to be
monitored for six weeks after treatment. In addition, skin biopsy samples from
drug and PDT treated sites will be analyzed for the presence of PDT response.
    "The data obtained so far from the trial have shown that SL017 Topical
Gel is safe and well-tolerated by patients treated with and without
photoactivation using an intense pulsed light source," said Mr. Thomas Woo,
Vice-President of Product Development for the Company. "As a topical PDT
agent, SL017 has the potential to treat a variety of skin conditions,
including AK, hair removal, acne, psoriasis, etc."
    AK is a pre-cancerous skin growth usually caused by prolonged accumulated
sun exposure. AK is treated by dermatologists and other physicians due to
concern that AK may progress to a malignant form of skin cancer, squamous cell
carcinomas. AK has an incidence of approximately 10 to 15% in the Caucasian
population globally. The American Medical Association estimates the U.S.
market to be about U.S. $250 million.
    In addition to the AK trial, the Company is also currently conducting a
50 patie nt Phase I/II study with SL017 Topical gel for hair removal
applications, and is completing pre-clinical studies of SL052 for PDT
treatment of prostate cancer. Quest has also recently signed an exclusive
multinational license agreement with Paramount Biosciences to develop and
commercialize SL017 for dermatology-related applications outside of Canada.
The Agreement further allows KMH Co. Ltd. to develop SL017 as a cosmetic for
hair removal in Asia and acne in South Korea.

    About Quest PharmaTech Inc.

    The Corporation is a publicly traded (TSX Venture Exchange: QPT),
Alberta-based drug development company committed to the development and
commercialization of new pharmaceutical products. It is developing a series of
products for the treatment of cancer and dermatological conditions based on
its unique photodynamic and sonodynamic therapy platform.

    "TSX Venture Exchange has neither approved nor disapproved of the
    information contained herein."

    %SEDAR: 00008400E




For further information:

For further information: Dr. Madi R.Madiyalakan, CEO, Tel.: (780)
448-1400 (Ext. 204), madi@questpharmatech.com, Web site:
www.questpharmatech.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890